Durvalumab + Enfortumab vedotin FDA Approval for Muscle Invasive Bladder Cancer (MIBC): VOLGA
From Oncology Brothers: Practice-Changing Cancer Discussions · · 25 min
This plays from the publisher's own server. We do not host a copy.
Description
In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas from Fred Hutch Cancer Center to discuss the recent FDA approval of the durvalumab plus enfortumab vedotin (EV) regimen for cisplatin-ineligible muscle-invasive bladder cancer (MIBC), based on the findings from the VOLGA trial.
Join us as we explored:
- The evolution of treatment standards for MIBC over the past 2 years
- Key insights from the VOLGA trial, including study design, findings, and clinical implications
- The significance of event-free survival (EFS) and overall survival (OS) rates in the context of this new regimen
- The balance between overtreatment and undertreatment in patient care
- The side effect profiles of durvalumab and enfortumab vedotin, and how they impact treatment decisions
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
• X/Twitter: https://x.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and share your thoughts in the comments!
#BladderCancer, #MIBC, #Durvalumab, #EnfortumabVedotin, #VOLGATrial
Back to Oncology Brothers: Practice-Changing Cancer Discussions · Report a problem